Healthcare and Life Sciences

Format: 2017-01-21
Format: 2017-01-21
November 18, 2016 | 101 Pages | SKU: IRTNTR10849

Overview of the lung cancer therapeutics market

According to the market research analysts at Technavio, the lung cancer therapeutics market is anticipated to witness fast-paced growth at a CAGR of more than 9% during the forecast period. With the growing demand for targeted therapies, the market for lung cancer therapeutics is likely to have a positive impact over the coming years. Targeted therapy is a novel treatment that involves targeting cancer-specific proteins, genes, cells or the tissue that leads to cancer growth and survival. Targeted therapies act by blocking the growth and spread of cancer cells besides limiting the damage to healthy cells. Moreover, targeted therapies have better efficacy over conventional therapies such as surgical resection, platinum-based chemotherapy, and radiation therapy. This has impelled the vendors to increasingly focus on developing targeting therapies in combination with traditional ones. Moreover, targeted therapies may have lesser side effects as compared with chemotherapy and radiation, which will lead to their increased adoption by physicians in the future.

In terms of geographical regions, the Americas led the global lung cancer therapeutics market and is likely to be the highest revenue contributor in the coming years. The presence of a large patient pool with lung cancer is one of the primary drivers of this market in the Americas, especially the US. Also, the increasing acceptance of targeted therapy for the treatment of lung cancer will bolster this market’s growth in the region. Some of the existing targeted therapies that are approved by the US FDA include bevacizumab (Avastin), erlotinib (Tarceva), gefitinib (Iressa), and ramucirumab (Cyramza). With the increasing adoption of targeted therapies


November 17, 2016 | 115 Pages | SKU: IRTNTR10837

Overview of the minimally invasive spine surgery market

According to the market research analysts at Technavio, the minimally invasive (MI) spine surgery market is anticipated to witness impressive growth and will post a CAGR of more than 7% during the forecast period. With the increasing popularity of physician-owned ambulatory surgical centers (ASCs), the market for MI spine surgery is expected to have a positive outlook over the coming years. The MI procedure performed for implantation of cervical implants is safe and considerably reduces the risk of infections, the need for blood transfusion, and the duration of hospital stays. This has encouraged surgeons to carry out these surgical procedures in outpatient settings and ASCs. Moreover, this trend is likely to continue as many complicated open surgeries will undergo rapid transition to MI surgeries. This also presents an opportunity for surgeons to invest setting their own ASCs to perform various cervical spine surgeries in outpatient settings. Additionally, most insurance companies provide high reimbursements for MI surgeries carried out in ASCs compared with hospitals. This will also encourage surgeons to opt for MI spine procedures over the coming years.

In terms of geography, the Americas accounted for the majority of market shares and will continue to lead the market over the next four years. According to a recent research study, more than 65 million people in the US are suffering from neck and back pain. Lower back pain is a primarily associated with spinal disorders, such as herniated discs, degenerative disc disease, spondylolisthesis, slipped disc, spinal stenosis,


November 16, 2016 | 94 Pages | SKU: IRTNTR10815

Overview of the global surgical navigation systems market

According to the market research analysts at Technavio, the global surgical navigation systems market is anticipated to witness impressive growth and will post a CAGR of more than 7% during the forecast period. Surgical navigation systems with various interfaces connected to it like interoperative imaging modalities, monitor display, and other tracking technologies serve as a support system in the majority of image-guided surgeries performed nowadays. Moreover, most modern surgeries like sentinel lymph node biopsy in breast cancer, post-traumatic zygomatic deformity, adult liver cancer, pulmonary artery denervation, and pedicle screw fixation in spine surgeries use surgical navigation system. Newer dimensions of applications in these therapy areas, as well as others, are being explored by surgeons and researchers in clinical trials, which is expected to reveal more diversified areas for its application. The increasing usefulness of surgical navigation systems along with the rising number of newer application areas acts as a major driving force for the surgical navigation systems market.

In terms of geography, the Americas accounted for the highest market shares during 2015 and will continue to lead the market over the next four years. The US was the leading revenue contributor in the region. The growth of the surgical navigation system market is attributed to the augmented adoption of technologically advanced surgical navigation systems. With the FDA approvals of surgical navigation systems, vendors are also focussing on developing a wider range of innovative surgical navigation tools to generate revenues. Furthermore, sales of the


November 15, 2016 | 76 Pages | SKU: IRTNTR10797

Overview of the global alopecia drugs market

The global alopecia drugs market is anticipated to grow at a steady rate and will post a CAGR of more than 5% during the forecast period. The increasing popularity of off-label and over-the-counter (OTC) drugs will drive the growth prospects for the global alopecia drugs market during the forecast period. Off-label drugs are used extensively by the consumers because the exact therapy targeted at remission of alopecia is currently unavailable. For instance, AVODART is approved for the treatment of prostate cancer, but this drug is also used for the treatment of alopecia. Such drugs are used in the absence of any proven remission track and can be a threat to the market’s growth in the future. However, at present, the increasing use of off-label drugs is fuelling the sale of these drugs. Also, these drugs are being used for unapproved clinical indication or extension to a milder form of approved indication or extension to related conditions. For instance, alopecia market heavily uses spironolactone and cyclosporine, which are primarily approved for other indications.

In terms of geography, the Americas accounted for the maximum market share in 2015 because the US was the largest revenue contributor in the region. During the forecast period, the Americas will continue to dominate the market due to the increasing awareness about the disease and drugs in the region. Furthermore, the changing lifestyle of individuals is resulting in hormonal imbalances due to increased stress, consumption of junk food, and physical inactivity. Also, the increasing rate of hormonal imbalances in the region can cause disorders that will increase the consumption of drugs.

Competitive landscape and key vendors

The leading vendors of the market are investing extensively in R&D of new drugs because there are no effective treatment options available for


November 14, 2016 | 101 Pages | SKU: IRTNTR10792

Overview of the global in-vitro diagnostics instruments market

The global in-vitro diagnostics (IVD) instruments market is anticipated to grow at a steady rate and will post a CAGR of close to 10% during the forecast period. The increasing demand for personalized medicine is driving the growth prospects of the market during the forecast period. Personalized medicines can be developed by the identification of a defective protein and gene structure of the patient. For instance, tests developed by Roche Diagnostics and Qiagen can identify defective proteins and genes extracted from tissues and develop advanced companion diagnostics to target individuals that respond to specific treatments. Also, the demand for personalized medicines is increasing in the oncology therapeutic area because it facilitates better patient management and enables individualized treatment through diagnostic tests for real-time and rapid results. Furthermore, this growing demand encourages many leading pharmaceutical companies to develop personalized medicine and offer incentives for cancer therapies. Moreover, one of the advantages of developing personalized treatment is that it enables better channeling of patient diagnostic information and communication of results to clinicians.

In terms of geography, the Americas accounted for the maximum market share and is expected to dominate the market during the next four years. Factors such as the changing lifestyle, increased alcohol consumption, smoking, and unhealthy food habits are driving the need for personalized treatment among patients in the region. Also, advancements in new technology and subsequent product launches will drive the growth prospects for the market in the Americas.

Competitive landscape and key vendors


November 14, 2016 | 88 Pages | SKU: IRTNTR10791

Overview of the global urology robotic surgery market

The global urology robotic surgery market is anticipated to grow at a steady rate and will post a CAGR of around 8% during the forecast period. The growing preference for minimally invasive (MI) surgeries over open surgical methods will drive the growth prospects for the global urology robotic surgery market during the forecast period. With the increasing preference for MI surgeries, the adoption of robotic-assisted techniques is also increasing. To enhance the overall surgical outcome by reducing the recovery time, hospital stay, and postoperative pain, most surgeons prefer robotics to perform complicated surgeries in areas such as urology and gynecology. Robot-assisted techniques allow precise movement of instruments and give a better view of the target area compared to other conventional techniques. Also, robotics is used to perform prostatectomies for prostate cancer and operations on the colon, bladder, rectum, and kidney for the treatment of chronic diseases. This recent rise in the number of surgical procedures is expected to drive the global urology robotic surgery market during the estimated period.

In 2015, the Americas accounted for the maximum market share and will continue to dominate the market until the end of 2020. It has been noted that the growing incidence of urology disorders is fueling the growth prospects for the market in the region. Another factor contributing to the market’s growth in the Americas is the emergence of nano-robotics. Moreover, to gain market shares, most vendors in the market are focusing on R&D activities that will lead to the development of advanced robotic systems. The availability of such advanced robotic systems


Pages